Claims for Patent: 5,603,929

Summary for Patent: 5,603,929

Title:	Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
Abstract:	Disclosed are storage-stable preserved ophthalmic compositions containing acidic drugs in combination with polymeric quaternary ammonium compounds and boric acid.
Inventor(s):	Desai; Suketu D. (Fort Worth, TX), Nelms; Diane S. (Fort Worth, TX)
Assignee:	Alcon Laboratories, Inc. (Fort Worth, TX)
Application Number:	08/340,763
Patent Claims:	1. A storage stable ophthalmic composition comprising a therapeutically effective amount of one or more acidic ophthalmic agents, a combination of an antimicrobial polymeric quaternary ammonium compound and boric acid in an amount effective to meet at least the minimum United States Pharmacopeia XXII and European Pharmacopeia (1994) preservative effectiveness requirements, and an ophthalmically acceptable vehicle; wherein the acidic ophthalmic agent is selected from the group consisting of anti-glaucoma and non-steroidal anti-inflammatory agents; provided that the composition does not contain a viscosity-enhancing amount of polyvinyl alcohol. 2. The composition of claim 1 wherein the ophthalmic agent is a non-steroidal anti-inflammatory agent. 3. The composition of claim 2 wherein the non-steroidal anti-inflammatory agent comprises an aryl- or heteroaryl-alkanoic acid, or an ophthalmically acceptable salt, ester, amide, or prodrug thereof. 4. The composition of claim 3 wherein the non-steroidal anti-inflammatory agent is selected from the group consisting of: diclofenac, flurbiprofen, suprofen, bromfenac, keterolac, indomethacin, ketaprofen, and ophthalmically acceptable salts, esters, amides or prodrugs thereof. 5. The composition of claim 4 wherein the non-steroidal anti-inflammatory agent is selected from the group consisting of diclofenac and its ophthalmically acceptable salts, esters, amides, or prodrugs thereof. 6. The composition of claim 4 wherein the non-steroidal anti-inflammatory agent is selected from the group consisting of suprofen and its ophthalmically acceptable salts, esters, amides, or prodrugs thereof. 7. The composition of claim 4 wherein the non-steroidal anti-inflammatory agent is selected from the group consisting of bromfenac and its ophthalmically acceptable salts, esters, amides, or prodrugs thereof. 8. The composition of claim 7 wherein the antimicrobial polymeric quaternary ammonium compound is polyquaternium 1. 9. The composition of claim 8 wherein the polyquaternium 1 has a number average molecular weight from 2,000 to 30,000. 10. The composition of claim 9 wherein the polyquaternium 1 has a number average molecular weight from 3,000 to 14,000. 11. The composition of claim 1 wherein the concentration of the antimicrobial polymeric quaternary ammonium compound is between about 0.00001 and about 3 percent by weight. 12. The composition of claim 11 wherein the concentration of the antimicrobial polymeric quaternary ammonium compound is between about 0.001 and about 0.1 percent by weight. 13. The composition of claim 12 wherein the concentration of the antimicrobial polymeric quaternary ammonium compound is between about 0.001 and about 0.05 percent by weight. 14. The composition of claim 1 wherein the ophthalmically active forms of boric acid are selected from the group consisting of boric acid, ophthalmically acceptable acid addition salts of boric acid and borate-polyol complexes. 15. The composition of claim 1 wherein the concentration of boric acid is between about 0.3 and about 5.0 percent by weight. 16. The composition of claim 15 wherein the concentration of boric acid or ophthalmically active forms thereof is between about 0.3 and about 3 percent by weight. 17. The composition of claim 16 wherein the concentration of boric acid or ophthalmically active forms thereof is between about 0.5 and about 2 percent by weight. 18. The composition of claim 14 wherein the ophthalmically active forms of boric acid are water soluble borate-polyol complexes having a molar ratio of borate to polyol from 1:1 to 1:10. 19. An ophthalmic formulation comprising diclofenac or an ophthalmically acceptable salt, ester, amide or prodrug thereof, and a combination of an antimicrobial polymeric quaternary ammonium compound and boric acid in an amount effective to meet at least the minimum United States Pharmacopeia XXII and European Pharmacopeia (1994) preservative effectiveness requirements; provided, that the formulation does not contain a viscosity-enhancing amount of polyvinyl alcohol. 20. The formulation of claim 19 wherein the formulation comprises sodium diclofenac, boric acid, mannitol, polyquaternium 1 and a comfort-enhancing agent.